Prediction in Rectal Cancer

Seminars in Radiation Oncology

Volumn 22, Issue 2, 2012, Pages 175-183

  Zeestraten, Eliane C M ^a   Kuppen, Peter J K ^a   Van de Velde, Cornelis J H ^a   Marijnen, Corrie A M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; RAS PROTEIN;

ALLELIC IMBALANCE; ANTIANGIOGENIC THERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SCINTISCANNING; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHROMOSOME 18Q; CLINICAL DECISION MAKING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC SURGERY; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; MICROSURGERY; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RECTUM CANCER; RECTUM RESECTION; RECURRENCE RISK; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECTAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84857585047     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2011.12.005     Document Type: Review

References (115)

1. Bujko K., Nowacki M.P., Nasierowska-Guttmejer A., et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: Report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004, 72:15-24.
2. Smith N., Brown G. Preoperative staging of rectal cancer. Acta Oncol 2008, 47:20-31.
3. Nagtegaal I.D., van Krieken J.H. The role of pathologists in the quality control of diagnosis and treatment of rectal cancer-an overview. Eur J Cancer 2002, 38:964-972.
4. Heald R.J., Ryall R.D. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986, 1:1479-1482.
5. Van Gijn W., Marijnen C.A., Nagtegaal I.D., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-Year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011, 12:575-582.
6. Bosset J.F., Collette L., Calais G., et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006, 355:1114-1123.
7. Blomqvist L., Glimelius B. The "good", the "bad", and the "ugly" rectal cancers. Acta Oncol 2008, 47:5-8.
8. Haustermans K., Debucquoy A., Lambrecht M. The ESTRO Breur lecture 2010: Toward a tailored patient approach in rectal cancer. Radiother Oncol 2011.
9. McShane L.M., Altman D.G., Sauerbrei W., et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2005, 2:416-422.
10. Martling A.L., Holm T., Rutqvist L.E., et al. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet 2000, 356:93-96.
11. Kapiteijn E., Marijnen C.A., Colenbrander A.C., et al. Local recurrence in patients with rectal cancer diagnosed between 1988 and 1992: A population-based study in the west Netherlands. Eur J Surg Oncol 1998, 24:528-535.
12. Kapiteijn E., Marijnen C.A., Nagtegaal I.D., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001, 345:638-646.
13. Sebag-Montefiore D., Stephens R.J., Steele R., et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): A multicentre, randomised trial. Lancet 2009, 373:811-820.
14. Roh M.S., Colangelo L.H., O'Connell M.J., et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009, 27:5124-5130.
15. Gérard J.P., Conroy T., Bonnetain F., et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203. J Clin Oncol 2006, 24:4620-4625.
16. Marijnen C.A., van de Velde C.J., Putter H., et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: Report of a multicenter randomized trial. J Clin Oncol 2005, 23:1847-1858.
17. Peeters K.C., van de Velde C.J., Leer J.W., et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: Increased bowel dysfunction in irradiated patients-A Dutch colorectal cancer group study. J Clin Oncol 2005, 23:6199-6206.
18. Birgisson H., Påhlman L., Gunnarsson U., et al. Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 2005, 23:6126-6131.
19. Birgisson H., Påhlman L., Gunnarsson U., et al. Late adverse effects of radiation therapy for rectal cancer-A systematic overview. Acta Oncol 2007, 46:504-516.
20. Lange M.M., van de Velde C.J. Urinary and sexual dysfunction after rectal cancer treatment. Nat Rev Urol 2011, 8:51-57.
21. Braendengen M., Tveit K.M., Berglund A., et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 2008, 26:3687-3694.
22. Fleming F.J., Påhlman L., Monson J.R. Neoadjuvant therapy in rectal cancer. Dis Colon Rectum 2011, 54:901-912.
23. Habr-Gama A., de Souza P.M., Ribeiro U., et al. Low rectal cancer: Impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum 1998, 41:1087-1096.
24. Habr-Gama A., Perez R.O., Sabbaga J., et al. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: Results of a prospective study using additional chemotherapy during the resting period. Dis Colon Rectum 2009, 52:1927-1934.
25. Rajput A., Bullard Dunn K. Surgical management of rectal cancer. Semin Oncol 2007, 34:241-249.
26. Bretagnol F., Merrie A., George B., et al. Local excision of rectal tumours by transanal endoscopic microsurgery. Br J Surg 2007, 94:627-633.
27. Langer C., Liersch T., Süss M., et al. Surgical cure for early rectal carcinoma and large adenoma: Transanal endoscopic microsurgery (using ultrasound or electrosurgery) compared to conventional local and radical resection. Int J Colorectal Dis 2003, 18:222-229.
28. Heintz A., Mörschel M., Junginger T. Comparison of results after transanal endoscopic microsurgery and radical resection for T1 carcinoma of the rectum. Surg Endosc 1998, 12:1145-1148.
29. Lee W., Lee D., Choi S., et al. Transanal endoscopic microsurgery and radical surgery for T1 and T2 rectal cancer. Surg Endosc 2003, 17:1283-1287.
30. Winde G., Nottberg H., Keller R., et al. Surgical cure for early rectal carcinomas (T1). Transanal endoscopic microsurgery vs. anterior resection. Dis Colon Rectum 1996, 39:969-976.
31. Bentrem D.J., Okabe S., Wong W.D., et al. T1 adenocarcinoma of the rectum: Transanal excision or radical surgery?. Ann Surg 2005, 242:472-477.
32. Borschitz T., Junginger T. [Progress report about the 1st workshop on local excision of rectal cancer]. Zentralbl Chir 2007, 132:99-105.
33. Garcia-Aguilar J., Mellgren A., Sirivongs P., et al. Local excision of rectal cancer without adjuvant therapy: A word of caution. Ann Surg 2000, 231:345-351.
34. Endreseth B.H., Myrvold H.E., Romundstad P., et al. Transanal excision vs. major surgery for T1 rectal cancer. Dis Colon Rectum 2005, 48:1380-1388.
35. Tjandra J.J., Kilkenny J.W., Buie W.D., et al. Practice parameters for the management of rectal cancer (revised). Dis Colon Rectum 2005, 48:411-423.
36. Habr-Gama A., Perez R.O., São Julião G.P., et al. Nonoperative approaches to rectal cancer: A critical evaluation. Semin Radiat Oncol 2011, 21:234-239.
37. Bujko K., Nowacki M.P., Nasierowska-Guttmejer A., et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006, 93:1215-1223.
38. Ngan S., Fisher R., Goldstein D. A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: An intergroup trial (TROG, AGITG, CSSANZ, RACS). J Clin Oncol 2010, 28:3509. [abstr].
39. Horisberger K., Treschl A., Mai S., et al. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: Results of a phase II Margit trial. Int J Radiat Oncol Biol Phys 2009, 74:1487-1493.
40. Machiels J.P., Sempoux C., Scalliet P., et al. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol 2007, 18:738-744.
41. Rödel C., Arnold D., Hipp M., et al. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 2008, 70:1081-1086.
42. Weiss C., Arnold D., Dellas K., et al. Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials. Int J Radiat Oncol Biol Phys 2010, 78:472-478.
43. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
44. Giantonio B.J., Catalano P.J., Meropol N.J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25:1539-1544.
45. Willett C.G., Duda D.G., di T.E., et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase II study. J Clin Oncol 2009, 27:3020-3026.
46. Kabbinavar F.F., Schulz J., McCleod M., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005, 23:3697-3705.
47. Ebos J.M., Lee C.R., Cruz-Munoz W., et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
48. Pàez-Ribes M., Allen E., Hudock J., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
49. Lahaye M.J., Engelen S.M., Nelemans P.J., et al. Imaging for predicting the risk factors-The circumferential resection margin and nodal disease-Of local recurrence in rectal cancer: A meta-analysis. Semin Ultrasound CT MR 2005, 26:259-268.
50. Garcia-Aguilar J., Pollack J., Lee S.H., et al. Accuracy of endorectal ultrasonography in preoperative staging of rectal tumors. Dis Colon Rectum 2002, 45:10-15.
51. Gualdi G.F., Casciani E., Guadalaxara A., et al. Local staging of rectal cancer with transrectal ultrasound and endorectal magnetic resonance imaging: Comparison with histologic findings. Dis Colon Rectum 2000, 43:338-345.
52. Mackay S.G., Pager C.K., Joseph D., et al. Assessment of the accuracy of transrectal ultrasonography in anorectal neoplasia. Br J Surg 2003, 90:346-350.
53. Bipat S., Glas A.S., Slors F.J., et al. Rectal cancer: Local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging-A meta-analysis. Radiology 2004, 232:773-783.
54. Brown G., Richards C.J., Bourne M.W., et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology 2003, 227:371-377.
55. Beets-Tan R.G., Beets G.L. Local staging of rectal cancer: A review of imaging. J Magn Reson Imaging 2011, 33:1012-1019.
56. Dresen R.C., Peters E.E., Rutten H.J., et al. Local recurrence in rectal cancer can be predicted by histopathological factors. Eur J Surg Oncol 2009, 35:1071-1077.
57. Zenni G.C., Abraham K., Harford F.J., et al. Characteristics of rectal carcinomas that predict the presence of lymph node metastases: Implications for patient selection for local therapy. J Surg Oncol 1998, 67:99-103.
58. Maas M., Nelemans P.J., Valentini V., et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: A pooled analysis of individual patient data. Lancet Oncol 2010, 11:835-844.
59. O'Neill B.D., Brown G., Heald R.J., et al. Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. Lancet Oncol 2007, 8:625-633.
60. Allegra C.J., Paik S., Colangelo L.H., et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003, 21:241-250.
61. Galizia G., Lieto E., Ferraraccio F., et al. Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res 2004, 10:3490-3499.
62. Garrity M.M., Burgart L.J., Mahoney M.R., et al. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: A North Central Cancer Treatment Group Study. J Clin Oncol 2004, 22:1572-1582.
63. Rosati G., Chiacchio R., Reggiardo G., et al. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: Relationships with tumor recurrence and survival. Tumour Biol 2004, 25:258-263.
64. Winder T., Lenz H.J. Molecular predictive and prognostic markers in colon cancer. Cancer Treat Rev 2010, 36:550-556.
65. Popat S., Houlston R.S. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 2005, 41:2060-2070.
66. Leong K.J., Wei W., Tannahill L.A., et al. Methylation profiling of rectal cancer identifies novel markers of early-stage disease. Br J Surg 2011, 98:724-734.
67. Barault L., Veyrie N., Jooste V., et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008, 122:2255-2259.
68. Samuels Y., Wang Z., Bardelli A., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
69. Velho S., Oliveira C., Ferreira A., et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005, 41:1649-1654.
70. Kato S., Iida S., Higuchi T., et al. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer 2007, 121:1771-1778.
71. Nosho K., Kawasaki T., Ohnishi M., et al. PIK3CA mutation in colorectal cancer: Relationship with genetic and epigenetic alterations. Neoplasia 2008, 10:534-541.
72. Ogino S., Nosho K., Kirkner G.J., et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009, 27:1477-1484.
73. Rodrigsuez-Viciana P., Warne P.H., Dhand R., et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994, 370:527-532.
74. Gupta S., Ramjaun A.R., Haiko P., et al. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 2007, 129:957-968.
75. Shaw R.J., Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441:424-430.
76. Ikenoue T., Kanai F., Hikiba Y., et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005, 65:4562-4567.
77. Samowitz W.S., Curtin K., Schaffer D., et al. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: A population-based study. Cancer Epidemiol Biomarkers Prev 2000, 9:1193-1197.
78. Brink M., de Goeij A.F., Weijenberg M.P., et al. K-ras oncogene mutations in sporadic colorectal cancer in the Netherlands cohort study. Carcinogenesis 2003, 24:703-710.
79. Ogino S., Nosho K., Kirkner G.J., et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009, 58:90-96.
80. Samowitz W.S., Albertsen H., Herrick J., et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005, 129:837-845.
81. Nosho K., Irahara N., Shima K., et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS ONE 2008, 3:e3698.
82. He Y., Van't Veer L.J., Mikolajewska-Hanclich I., et al. PIK3CA mutations predict local recurrences in rectal cancer patients. Clin Cancer Res 2009, 15:6956-6962.
83. Notterman D.A., Alon U., Sierk A.J., et al. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res 2001, 61:3124-3130.
84. Lin Y.M., Furukawa Y., Tsunoda T., et al. Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. Oncogene 2002, 21:4120-4128.
85. Birkenkamp-Demtroder K., Christensen L.L., Olesen S.H., et al. Gene expression in colorectal cancer. Cancer Res 2002, 62:4352-4363.
86. Alon U., Barkai N., Notterman D.A., et al. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci U S A 1999, 96:6745-6750.
87. Kwon H.C., Kim S.H., Roh M.S., et al. Gene expression profiling in lymph node-positive and lymph node-negative colorectal cancer. Dis Colon Rectum 2004, 47:141-152.
88. Friederichs J., Rosenberg R., Mages J., et al. Gene expression profiles of different clinical stages of colorectal carcinoma: Toward a molecular genetic understanding of tumor progression. Int J Colorectal Dis 2005, 20:391-402.
89. Birkenkamp-Demtroder K., Olesen S.H., Sørensen F.B., et al. Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut 2005, 54:374-384.
90. Komuro K., Tada M., Tamoto E., et al. Right- and left-sided colorectal cancers display distinct expression profiles and the anatomical stratification allows a high accuracy prediction of lymph node metastasis. J Surg Res 2005, 124:216-224.
91. Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell 2011, 144:646-674.
92. Speetjens F.M., de Bruin E.C., Morreau H., et al. Clinical impact of HLA class I expression in rectal cancer. Cancer Immunol Immunother 2008, 57:601-609.
93. de Heer P., de Bruin E.C., Klein-Kranenbarg E., et al. Caspase-3 activity predicts local recurrence in rectal cancer. Clin Cancer Res 2007, 13:5810-5815.
94. de Bruin E.C., van de Velde C.J., van de Pas S., et al. Prognostic value of apoptosis in rectal cancer patients of the dutch total mesorectal excision trial: Radiotherapy is redundant in intrinsically high-apoptotic tumors. Clin Cancer Res 2006, 12:6432-6436.
95. Smith F.M., Reynolds J.V., Miller N., et al. Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol 2006, 32:55-64.
96. Maor Y., Nadler M., Barshack I., et al. Endoscopic ultrasound staging of rectal cancer: Diagnostic value before and following chemoradiation. J Gastroenterol Hepatol 2006, 21:454-458.
97. Denecke T., Rau B., Hoffmann K.T., et al. Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: Is there a benefit in using functional imaging?. Eur Radiol 2005, 15:1658-1666.
98. Barbaro B., Fiorucci C., Tebala C., et al. Locally advanced rectal cancer: MR imaging in prediction of response after preoperative chemotherapy and radiation therapy. Radiology 2009, 250:730-739.
99. Evans J., Patel U., Brown G. Rectal cancer: Primary staging and assessment after chemoradiotherapy. Semin Radiat Oncol 2011, 21:169-177.
100. Patel U.B., Taylor F., Blomqvist L., et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 2011, 29:3753-3760.
101. Lambrecht M., Deroose C., Roels S., et al. The use of FDG-PET/CT and diffusion-weighted magnetic resonance imaging for response prediction before, during and after preoperative chemoradiotherapy for rectal cancer. Acta Oncol 2010, 49:956-963.
102. Kuremsky J.G., Tepper J.E., McLeod H.L. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2009, 74:673-688.
103. Spindler K.L., Nielsen J.N., Lindebjerg J., et al. Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. Int J Radiat Oncol Biol Phys 2006, 66:500-504.
104. Huerta S., Hrom J., Gao X., et al. Tissue microarray constructs to predict a response to chemoradiation in rectal cancer. Dig Liver Dis 2010, 42:679-684.
105. Ghadimi B.M., Grade M., Difilippantonio M.J., et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 2005, 23:1826-1838.
106. Liersch T., Grade M., Gaedcke J., et al. Preoperative chemoradiotherapy in locally advanced rectal cancer: Correlation of a gene expression-based response signature with recurrence. Cancer Genet Cytogenet 2009, 190:57-65.
107. Watanabe T., Komuro Y., Kiyomatsu T., et al. Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Res 2006, 66:3370-3374.
108. Rimkus C., Friederichs J., Boulesteix A.L., et al. Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer. Clin Gastroenterol Hepatol 2008, 6:53-61.
109. Horst D., Kriegl L., Engel J., et al. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008, 99:1285-1289.
110. Horst D., Scheel S.K., Liebmann S., et al. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol 2009, 219:427-434.
111. Takahashi S., Kamiyama T., Tomaru U., et al. Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients. Oncol Rep 2010, 24:1201-1212.
112. Saigusa S., Tanaka K., Toiyama Y., et al. Immunohistochemical features of CD133 expression: Association with resistance to chemoradiotherapy in rectal cancer. Oncol Rep 2010, 24:345-350.
113. Yasuda H., Tanaka K., Saigusa S., et al. Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer. Oncol Rep 2009, 22:709-717.
114. Bengala C., Bettelli S., Bertolini F., et al. Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann Oncol 2009, 20:469-474.
115. Valentini V., van Stiphout R.G., Lammering G., et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol 2011, 29:3163-3172.